Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Shareholders Approve Genoptix Merger

NEW YORK (GenomeWeb) – Rosetta Genomics announced today that its shareholders have approved its proposed merger with Genoptix.

Late last year, Genoptix agreed to acquire Rosetta for $10 million in cash, but the deal was scuttled after failing to garner enough support from Rosetta shareholders. Several months later, the companies signed a new merger agreement that valued Rosetta at $9 million.

Rosetta said that its shareholders have approved the latest agreement and that the merger is now slated to close on May 27. Following completion of the deal, Rosetta will become a privately held subsidiary of Genoptix, and its shares will cease to trade on the Nasdaq.

During midday trading, shares of Rosetta were down less than 1 percent to $.43.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.